Nasdaq:BCRX
BIOCRYST PHARMACEUTICALS INC
A biopharmaceutical company that has achieved record revenue and profitability following a period of heavy investment in R&D and market expansion.
Key Metrics
Investment Thesis
Bull Case
The stock presents a compelling opportunity for investors seeking exposure to a biopharma company that has finally crossed the profitability threshold after years of reinvestment. With $89.7M in cash and $185M in marketable securities, BCRX is well-capitalized to withstand industry volatility and fund its extensive $166.1M annual R&D pipeline without immediate need for dilutive fundraising. The trajectory of revenue growth combined with a return to positive net income suggests a maturing business model capable of delivering sustained shareholder value.
Bear Case
Despite recent profitability, the company carries a substantial retained earnings deficit of -$1.51B which could limit future dividend potential or force equity issuance if R&D costs escalate. The heavy reliance on marketable securities ($612M total) exposes the firm to interest rate risk and potential unrealized losses that could impact the balance sheet quality. Additionally, the massive cash outflows from financing activities in the recent period indicate significant capital structure adjustments are still underway, creating uncertainty around future liquidity needs.
About BIOCRYST PHARMACEUTICALS INC
BIOCRYST PHARMACEUTICALS INC (BCRX) operates within the pharmaceutical sector, leveraging its substantial cash reserves to fund research and development efforts aimed at delivering novel therapies. The company has recently achieved a significant turnaround in profitability, transitioning from years of losses to record revenue and net income in the most recent fiscal year. With minimal long-term debt and a robust operating cash flow, the firm is positioned to capitalize on market opportunities while managing its high operational expenses.
Analysis
Management Discussion
Management has executed a successful pivot from high-burn growth to profitability, evidenced by the $263.9M net profit and positive operating cash flow of $347.4M in the latest period. Despite paying down $300M in debt repayments and managing other financing outflows, the company maintained a healthy ending cash balance of $91.3M while growing revenue by nearly 100% year-over-year. The shift from a negative equity position to a manageable shareholders' equity deficit indicates that operational improvements are beginning to outweigh historical accumulated losses.
Industry Overview
The pharmaceutical industry is characterized by high regulatory barriers, intense competition for patent exclusivity, and a constant need for innovation to maintain market share. Companies in this sector typically operate with thin margins until products achieve blockbuster status, requiring substantial upfront investment in research and development before realizing significant returns. Current market dynamics favor firms that can demonstrate a clear path to profitability while managing the high costs of clinical trials and regulatory approvals.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $270.8M | $331.4M | $450.7M | $874.8M |
| Cost of Revenue | $6.4M | $4.5M | $12.3M | $19.1M |
| Gross Profit | $264.4M | $326.9M | $438.4M | $855.8M |
| Operating Expenses | $412.9M | $430.6M | $441.0M | $514.8M |
| Operating Income | $-148.4M | $-103.7M | $-2.5M | $341.0M |
| R&D | $253.3M | $216.6M | $174.6M | $166.1M |
| G&A | $159.4M | $213.9M | $266.1M | $348.6M |
| Stock-Based Comp | $44.7M | $55.6M | $65.4M | $85.1M |
| D&A | $1.4M | $1.7M | $1.2M | $1.4M |
| Other OpEx | $186.0K | $180.0K | $216.0K | $0 |
| Non-Operating Income | $-95.9M | $-122.5M | $-84.4M | $-73.6M |
| Interest Expense | $99.1M | $108.2M | — | — |
| Pre-Tax Income | $-244.4M | $-226.2M | $-87.0M | $267.4M |
| Income Tax | $2.7M | $310.0K | $1.9M | $3.5M |
| Continuing Ops | $-247.1M | $-226.5M | $-88.9M | $263.9M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-247.1M | $-226.5M | $-88.9M | $263.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-247.1M | $-226.5M | $-88.9M | $263.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $516.5M | $496.0M | $422.0M | $404.3M |
| Cash & Equivalents | $304.8M | $110.6M | $104.7M | $89.7M |
| Marketable Securities | — | — | — | $185.0M |
| Accounts Receivable | $50.6M | $57.0M | $79.1M | $106.8M |
| Inventory | $27.5M | $28.7M | $31.3M | $5.4M |
| Prepaid Expenses | $12.6M | $19.5M | $13.8M | $17.2M |
| Other Current Assets | $121.0M | $280.1M | $193.2M | $201.0K |
| Long-Term Assets | $33.5M | $21.0M | $68.5M | $109.8M |
| PP&E (Net) | $8.6M | $7.9M | $7.8M | $8.8M |
| Operating Leases | $6.8M | $8.7M | $8.1M | $7.5M |
| LT Investments | $18.1M | $0 | $20.3M | $61.2M |
| Other LT Assets | $0 | $4.4M | $32.3M | $32.3M |
| Total Assets | $550.0M | $517.0M | $490.4M | $514.2M |
| Current Liabilities | $105.5M | $150.0M | $160.4M | $196.1M |
| Accounts Payable | $14.4M | $20.9M | $11.6M | $15.8M |
| Current Leases | $2.4M | $1.1M | $937.0K | $317.0K |
| Other Current Liab | $1.2M | $25.2M | $34.5M | $53.5M |
| Long-Term Liabilities | $739.1M | $822.5M | $806.0M | $437.2M |
| Long-Term Debt | $231.6M | $303.2M | $314.9M | $0 |
| LT Operating Leases | $5.8M | $8.4M | $7.9M | $8.6M |
| Other LT Liab | $501.7M | $510.9M | $483.2M | $428.7M |
| Total Liabilities | $844.6M | $972.5M | $966.4M | $633.3M |
| Shareholders' Equity | $-294.6M | $-455.5M | $-475.9M | $-119.2M |
| Paid-In Capital | $1.16B | $1.22B | $1.29B | $1.38B |
| Retained Earnings | $-1.45B | $-1.68B | $-1.77B | $-1.51B |
| AOCI | $26.0K | $1.3M | $921.0K | $38.0K |
| Total L&E | $550.0M | $517.0M | $490.4M | $514.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-247.1M | $-226.5M | $-88.9M | $263.9M |
| Non-Cash Adjustments | $71.3M | $135.1M | $74.3M | $-20.6M |
| Working Capital Changes | $14.0M | $-3.7M | $-37.5M | $104.1M |
| Cash from Operations | $-161.8M | $-95.1M | $-52.0M | $347.4M |
| Cash from Investing | $-128.2M | $-131.5M | $52.6M | $-13.7M |
| Debt Issuances | — | $300.0M | $0 | $0 |
| Debt Repayments | — | — | — | $300.0M |
| Cash from Financing | $88.0M | $32.5M | $-5.8M | $-349.9M |
| FX Effect | $566.0K | $362.0K | $-936.0K | $1.3M |
| Net Change in Cash | $-201.5M | $-193.8M | $-6.1M | $-15.0M |
| Beginning Cash | $507.7M | $306.2M | $112.4M | $106.3M |
| Ending Cash | $306.2M | $112.4M | $106.3M | $91.3M |
Frequently Asked Questions
How does BIOCRYST PHARMACEUTICALS INC make money?
The company's financial profile suggests three primary drivers: significant revenue generated from core pharmaceutical sales supported by high accounts receivable, substantial capital allocation into research and development exceeding $166M to fuel pipeline growth, and strategic investments in long-term securities totaling over $600M indicating a focus on liquidity management and potential M&A or dividend opportunities.
What are the main risks for BCRX?
Investors must consider the historical accumulated deficit of over $1.5 billion which could pressure future earnings if R&D expenditures continue at current levels. The company faces risks associated with its massive marketable securities portfolio ($612M in long-term investments) subject to interest rate fluctuations and potential write-downs. Furthermore, the significant one-time cash flow outflows from financing (-$349.9M) and investing activities (-$13.7M) require careful monitoring to ensure sustainable capital structure management.
What is BCRX's competitive advantage?
The firm holds a distinct competitive moat through its massive accumulated cash and marketable securities ($89.7M cash plus $185M in securities), providing financial flexibility that few peers possess. Additionally, the company has successfully scaled its revenue growth from under $300M to nearly $900M while finally turning profitable, demonstrating strong product-market fit and operational efficiency improvements.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.